

Special Issue

Pancreatic Cancer: Pathomechanism, Diagnostics and Novel Treatment Options

Message from the Guest Editors

Pancreatic cancer (PC) represents one of the leading causes of cancer-related death. Despite the great research efforts, the PC-associated mortality continues to increase. Furthermore, PC is characterized by high clonal heterogeneity, and resistance to chemotherapy and radiotherapy. In addition, it is commonly diagnosed at an advanced stage, when treatment options are limited. Consequently, it is critical to find new diagnostic tools and therapeutic strategies that can be more efficient and accurate. In this context, we call all surgeons, physicians, and professionals from all the associated disciplines involved in the diagnostic and curative research and pathway of patients with PC (basic and translational science researchers, oncologists, surgeons, anesthesiologists, radiologists, intensivists, oncologists, nurses, nutritionists, etc.) to contribute to this Special Issue. Our vision is to provide the best currently available evidence on this important topic, providing all the necessary information to researchers and clinicians on core concepts at the forefront of PC research.

- pancreatic cancer
- chemotherapy
- radiotherapy
- immunotherapy
- biomarkers

Guest Editors

Dr. Konstantinos Dimas

Department of Pharmacology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 341500 Larissa, Greece

Dr. Dimitrios E. Magouliotis

Department of Cardiac Surgery Research, Lankenau Institute of Medical Research, Wynnewood, PA 19096, USA

Deadline for manuscript submissions

closed (30 September 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9

CiteScore 6.8

Indexed in PubMed



mdpi.com/si/171030

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](http://mdpi.com/journal/biomedicines)

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

